Volume 62, Issue 1, Pages 88-96 (July 2012) The Impact of Germline Genetic Variations in Hydroxysteroid (17-Beta) Dehydrogenases on Prostate Cancer Outcomes After Prostatectomy  Étienne Audet-Walsh, Judith Bellemare, Louis Lacombe, Yves Fradet, Vincent Fradet, Pierre Douville, Chantal Guillemette, Éric Lévesque  European Urology  Volume 62, Issue 1, Pages 88-96 (July 2012) DOI: 10.1016/j.eururo.2011.12.021 Copyright © 2011 European Association of Urology Terms and Conditions

Fig. 1 Schematic representation of sex steroid biosynthesis by multiple hydroxysteroid (17-beta) dehydrogenase enzymes. 17β-HSD=hydroxysteroid (17-beta) dehydrogenase; DHEA=dehydroepiandrosterone; DHEA-S=DHEA sulphate; 5-DIOL=androst-5-ene-3β, 17βdiol; 4-dione=androstenedione; TESTO=testosterone; A-dione=androstanedione; DHT=dihydrotestosterone; ADT=androsterone; 3α-DIOL=androstane-3α, 17βdiol; epi-ADT=epi-androsterone; 3β-DIOL=androstane-3β, 17βdiol; E1=oestrone; E2=oestradiol. European Urology 2012 62, 88-96DOI: (10.1016/j.eururo.2011.12.021) Copyright © 2011 European Association of Urology Terms and Conditions

Fig. 2 Germline variations in hydroxysteroid (17-beta) dehydrogenase type 2 (HSD17B2) and (A) risk of biochemical recurrence (BCR) in localised prostate cancer (PCa) cases (n=526) and (B) risk of progression in advanced PCa cases (n=213). Boxes shown within the main panel represent hazard ratios (HRs) and their 95% confidence intervals in multivariate analyses as described in Tables 2 and 3. Reference categories (HR: 1.00) are composed of individuals with a major allele as described in Tables 2 and 3. The triangle on the left side of the panel represents genetic linkage between haplotype-tagging single nucleotide polymorphisms tested in HSD17B2 for the localised PCa cohort (n=526). European Urology 2012 62, 88-96DOI: (10.1016/j.eururo.2011.12.021) Copyright © 2011 European Association of Urology Terms and Conditions

Fig. 3 Kaplan-Meier curves of (A) biochemical recurrence (BCR)–free survival in localised prostate cancer (PCa; n=526), (B) progression-free survival (PFS) in advanced PCa (n=213), and overall survival (OS) in advanced PCa. Information on single nucleotide polymorphisms significantly associated with the risk of BCR-free survival, PFS, or OS were included for these calculations based on the combined analyses. Log-rank p values are shown in each frame. PCa=prostate cancer; HR=hazard ratio; CI=confidence interval; BCR=biochemical recurrence. European Urology 2012 62, 88-96DOI: (10.1016/j.eururo.2011.12.021) Copyright © 2011 European Association of Urology Terms and Conditions